Skip to main content

Evaluating Outpatient Teclistamab Administration in Multiple Myeloma With Robert Rifkin, MD, FACP

Oncology Data Advisor® · Evaluating Outpatient Teclistamab Administration in Multiple Myeloma: Robert Rifkin, MD At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Robert Rifkin, MD, FACP, a Board-Certified Medical Oncologist and Hematologist at the Rocky Mountain Cancer Centers in Denver, Colorado, sat down with Oncology Data Advisor to discuss his study and presentation on the OPTEC trial, in which administration of the bispecific antibody teclistamab will be eva...

Continue reading

Nurse Navigation and Financial Toxicity Programs to Reduce Socioeconomic Disparities in ALL With Greg Knight, MD

In this interview from the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor speaks with Greg Knight, MD, Clinical Assistant Professor of Medicine at Levine Cancer Institute, about his presentation on the impacts of nurse navigation and other supportive care services for reducing socioeconomic disparities in acute lymphoblastic leukemia (ALL) treatment. Additionally, Dr. Knight describes Levine Cancer Institute's Financial Toxicity Tumor Board, the first program of its kind, and shares advice for how other centers can implement similar interventions for mitigating socioeconomic disparities experienced by their patients.  

Continue reading

Exploring Epcoritamab for Relapsed/Refractory Follicular Lymphoma: Dr. Matthew Hadfield, Dr. Alankrita Taneja, Dr. Tahi Ahmadi, and Dr. Jacqueline Nielsen

Recently, Genmab and AbbVie announced updated results of the phase 1/2 EPCORE™ NHL-1 trial of epcoritamab (epco) for patients with R/R follicular lymphoma. In this interview, Dr. Matthew Hadfield and Dr. Alankrita Taneja of the Fellows Forum speak with Dr. Tahi Ahmadi, Chief Medical Officer at Genmab, and Dr. Jacqueline Nielsen, Therapeutic Area Head for Hematology at AbbVie, about the significance of these results, the benefits of epcoritamab's subcutaneous administration, management of adverse events, and the future role of epcoritamab in follicular lymphoma treatment.  

Continue reading

Additional Advances in Multiple Myeloma Research and Clinical Trials With Shaji Kumar, MD

Currently, Dr. Shaji Kumar, Professor of Hematological Malignancies at the Mayo Clinic Cancer Center, is the chair of Optimizing Treatment Sequencing for Patients With Relapsed/Refractory Multiple Myeloma, a continuing medical education/nursing continuing professional development (CME/NCPD)–accredited live or virtual meeting series provided by i3 Health. In this interview, Dr. Kumar provides a glimpse into the exciting developments in multiple myeloma research that are covered in the program, including breaking updates from the 2022 American Society of Hematology (ASH) Annual Meeting.

Continue reading

Exploring the Primary Overall Survival Results of Axicabtagene Ciloleucel in the ZUMA-7 Trial With Jason Westin, MD

At the recent 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Jason Westin, Director of Lymphoma Clinical Research at MD Anderson Cancer Center, presented the primary overall survival analysis of the phase 3 ZUMA-7 trial investigating axicabtagene ciloleucel for relapsed/refractory large B-cell lymphomas. In this interview, he shares more with Oncology Data Advisor regarding the efficacy, safety, and future directions of this promising agent. 

Continue reading

Investigating Brentuximab Vedotin for Advanced-Stage Hodgkin Lymphoma With Habte Yimer, MD

At the recent American Society of Hematology (ASH) Annual Meeting, Dr. Habte Yimer of Texas Oncology sat down with Oncology Data Advisor to elaborate on the promising results of brentuximab vedotin for patients with advanced-stage classical Hodgkin lymphoma, including the most recent data and future directions for the trial.  

Continue reading

Updates on Trials of Zilovertamab and Brentuximab Vedotin in Lymphomas With Hun Lee, MD

At the recent American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor met with Dr. Hun Lee of MD Anderson to discuss the two abstracts that he presented there. Dr. Lee provided an update on the promising data for zilovertamab plus ibrutinib for patients with mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), and chronic lymphocytic leukemia (CLL), and for brentuximab vedotin plus nivolumab and chemotherapy for patients with Hodgkin lymphoma.  

Continue reading

CLL Society: A Valuable Resource for Patients and the Health Care Team, With Founder Brian Koffman, MD

In this interview, Oncology Data Advisor speaks with Dr. Brian Koffman, founder of CLL Society, a nonprofit organization focused on patient education, support, and research for chronic lymphocytic leukemia (CLL). Dr. Koffman shares his personal story and how it led him to establish CLL Society and explains how the valuable resources they provide can benefit both patients with CLL and the health care team members who treat and support them. 

Continue reading

Understanding Multiple Myeloma Treatment Patterns and Sequencing With Robert Rifkin, MD, FACP

At the recent 64th American Society of Hematology (ASH) Annual Meeting, Dr. Robert Rifkin, Medical Oncologist and Hematologist at Rocky Mountain Cancer Centers in Denver, Colorado, sat down with Oncology Data Advisor to discuss the research that he presented, titled Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry.  

Continue reading

Understanding Clonal Hematopoiesis in Hematologic Malignancies With Rahul Banerjee, MD, Jeremy Meier, MD, and Samuel Rubinstein, MD

Dr. Jeremy Meier and Dr. Samuel Rubinstein of the University of North Carolina (UNC) Chapel Hill are the first and senior author, respectively, of a recently published review paper entitled Game of Clones: Diverse Implications for Clonal Hematopoiesis in Lymphoma and Multiple Myeloma. In this interview for Blood Cancer Awareness Month, Oncology Data Advisor's Editorial Board member Dr. Rahul Banerjee speaks with Dr. Meier and Dr. Rubinstein about their work in this area and the future of clonal hematopoiesis research in hematologic malignancies. 

Continue reading

Investigating the Efficacy of HPN217 in Relapsed/Refractory Multiple Myeloma With Luke Walker, MD

At the recent 64th American Society of Hematology (ASH) Annual Meeting in New Orleans, Dr. Luke Walker, Chief Medical Officer of Harpoon Therapeutics, sat down with Oncology Data Advisor to discuss the results of a phase 1 trial of HPN217, a B-cell maturation antigen (BCMA)–targeting T-cell engager, which were presented at the meeting. Dr. Walker delves into the efficacy that HPN217 demonstrated in patients with relapsed/refractory multiple myeloma, including its tolerability and low risk of cytokine release syndrome (CRS).  

Continue reading

Oncology Data Advisor at the American Society of Hematology (ASH) 2023 Annual Meeting

At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. This podcast series features exclusive conversations on breaking data for novel therapies, technological innovations in hematology/oncology, efforts to reduce disparities and improve health equity, and more! Oncology Data Advisor® · Oncology D...

Continue reading

Reducing Stigmatizing Language in the Electronic Medical Record for More Equitable Care With Alex Boucher, MD

In this interview from the 2023 American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor speaks with Dr. Alex Boucher, Director of the Pediatric and Adult Sickle Cell Programs at the University of Minnesota Medical School, about his presentation on racial discrepancies in the use of stigmatizing language in hematology/oncology electronic medical records. Dr. Boucher explains the impact that stigmatizing language can have on patient care and ways to raise awareness for mitigating its use.  

Continue reading

Expanding Access to Brexucabtagene Autoleucel for Mantle Cell Lymphoma With Andre Goy, MD

In this interview from the American Society of Hematology (ASH) Annual Meeting, Oncology Data Advisor speaks with Dr. Andre Goy, Chair of the John Theurer Cancer Center and Hackensack University Medical Center, about his presentation on an expanded access study of brexucabtagene autoleucel (brexu-cel) for patients with mantle cell lymphoma who were ineligible for the ZUMA-2 and ZUMA-18 studies. Additionally, Dr. Goy shares insights into the growing arsenal of therapies for patients with high-risk mantle cell lymphoma. 

Continue reading

Addressing Ethical Concerns Around Artificial Intelligence in Cancer Care With Andrew Hantel, MD

In this interview from the 2023 American Society of Hematology (ASH) Annual Meeting, Dr. Andrew Hantel, Instructor in Medicine at Harvard Medical School, shares more about his presentation on oncologists' perspectives on ethical implications of artificial intelligence (AI) in cancer care, as well as ongoing efforts build a framework for the integration of AI into oncology care delivery.  

Continue reading

Highlights From the 2023 San Antonio Breast Cancer Symposium With Jason Mouabbi, MD

At the recent San Antonio Breast Cancer Symposium (SABCS), numerous updates were presented which have the potential to improve treatment outcomes for patients with breast cancer. After returning from the meeting, Dr. Jason Mouabbi, Assistant Professor of Breast Medical Oncology at MD Anderson Cancer Center and Editorial Board Member of Oncology Data Advisor, sat down to highlight some of the most exciting research presented, including the HER2CLIMB-02, MONARCH 3, and INAVO trials.  

Continue reading

New Lung Cancer Screening Guidelines With Brian Whang, MD, FACS

Oncology Data Advisor® · New Lung Cancer Screening Guidelines With Brian Whang Recently, the American Cancer Society recommended new lung cancer screening guidelines to shift the focus from quitting smoking, to helping all individuals who have smoked despite quitting 20 to 30 years prior. In this interview, Dr. Brian Whang, Medical Director of Lung Cancer Screening for Hartford Healthcare, discusses these new guidelines, what they mean, and why we should continue advocating for better...

Continue reading

Additional Advances in PI3K Inhibitor Research and Clinical Trials: Staying Ahead of Hyperglycemia and Rash Management With Janie Metsker, RN, BSN, CN-BN

Oncology Data Advisor® · Additional Advances in PI3K Inhibitor Research & Clinical Trials With Janie Metsker, RN, BSN, CN-BN Phosphatidylinositol-3-kinase (PI3K) inhibitors are effective treatment for patients with breast cancer but can be associated with significant hyperglycemia and rash. In this interview from the 48th Annual Oncology Nursing Society (ONS) Congress, Janie Metsker, RN, BSN, CN-BN, Clinical Coordinator at St. Luke's Koontz Center for Advanced Breast Cancer, share...

Continue reading

Reframing the Conversation in Metastatic Breast Cancer With Janie Metsker, RN, BSN, CN-BN

For patients with metastatic breast cancer (MBC), Breast Cancer Awareness Month can sometimes be demoralizing in light of pervasive public messaging about finding a cure and embracing survivorship. In this interview, Janie Metsker, RN, BSN, CN-BN, Clinical Coordinator at St. Luke's Koontz Center for Advanced Breast Cancer, shares ways to reframe the conversation in metastatic breast cancer to prioritize shared decision making, patients' individual goals, and redefining hope. Additionally, we hear a message from Justin Bray, a patient with metastatic breast cancer, about the importance for clinicians to form relationships with patients in order to understand and develop the best care for them throughout their journey.  

Continue reading

Exploring the ARTISTRY-7 Trial of Nemvaleukin Alfa in Ovarian Cancer With Noelle Cloven, MD

Oncology Data Advisor® · Exploring the ARTISTRY-7 Trial of Nemvaleukin Alfa in Ovarian Cancer With Noelle Cloven, MD At the recent American Society of Clinical Oncology (ASCO) Annual Meeting, Dr. Noelle Cloven, a Gynecologic Oncologist at the Sarah Cannon Research Institute at Texas Oncology, sat down with Oncology Data Advisor to further discuss her presentation this year encompassing the ongoing ARTISTRY-7 trial. This trial seeks to evaluate the safety and efficacy of nemvaleukin al...

Continue reading